Clinical Trial Update: A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CJC-1295 in HIV-infected individuals with visceral obesity has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Obesity

Drugs mentioned

• CJC-1295 (CJC-1295)

Snippet

Sponsor: ConjuChem | Conditions: Obesity, HIV Infections | Phase 2 | Status: TERMINATED